CD4 Count and Anti Retroviral Therapy for HIV Positive Patients With Cancer in Nigeria -A Pilot Study by Ntekim, Atara I. & Folasire, Ayo. M.
Clinical Medicine Insights: Oncology 2010:4 61–66
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology
OrIgInAL reseArCh
Clinical Medicine Insights: Oncology 2010:4  61
cD4 count and Anti Retroviral Therapy for HIV positive 
patients With cancer in nigeria -A pilot study
Atara I. ntekim and Ayo. M. Folasire
Department of radiation Oncology, University College hospital, Ibadan, nigeria.  
Corresponding author email: tarantekim@yahoo.com
Abstract
Background: Highly Active Anti Retroviral Treatment (HAART) improves the outcome of HIV positive patients treated for cancer. In 
our center HAART is only commenced in HIV positive patients with malignancy if the CD4 T lymphocyte count is less than 200 cells/ul. 
Presently, the outcome of treatment in these patients is poor.
Objective: To evaluate the influence of CD4 T- cell count and HAART on treatment outcome of HIV positive patients with cancer 
  managed at the oncology service of The University College Hospital, Ibadan- South West Nigeria.
Patients and methods: Twenty two adult HIV positive patients with malignancies who presented for treatment at our hospital from 
2007 to 2009 were closely monitored by the investigators. Relevant clinical data collected included age, sex, HIV status, type of 
  malignancy, CD4 counts, history of ART, ECOG performance status, prescribed oncology treatment with regularity of treatment and to 
follow up conditions.
Results: Twenty two patients aged between 26 and 67 years were evaluated. The performance status of all patients was at least ECOG 2. 
Three ART naive patients with initial CD4 counts 450 cells/ul and above were able to complete oncology treatment without HAART 
with good malignant disease control. Five other patients on HAART before the diagnosis of malignancy with CD4 counts 350 cells/ul 
and above were also able to complete their treatments on schedule with good outcome. Eight HAART naive patients with initial CD4 
counts less than 370 cells/ul had inconsistent treatments with poor outcome.
Conclusion: Based on these observations, we propose that HAART should be commenced on all HIV positive patients diagnosed with 
malignancy with an initial CD4 count less than 450 cells/ul in our environment. Further studies in low resource settings with appropriate 
sample sizes are however needed to validate these findings.
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Introduction
The  prevalence  of  HIV  infection  is  high  in  sub 
Sahara Africa and mortality from associated AIDS 
is  quite  high.  The  introduction  of  Highly  Active 
Anti   Retroviral Therapy (HAART) since 1996 has 
improved survival and quality of life with this disease 
especially in the developed countries due to   reduction 
in opportunistic infections.1 This improvement is also 
noticed in Sub Sahara Africa though access to ART is 
still a problem to most patients. The estimated cov-
erage of ART in sub Sahara Africa is about 44%.2 
As HIV infected persons are living   longer, non AIDS 
defining  malignancies  are    becoming  increasingly 
diagnosed.3
The  mortality  from  cancer  in  underdeveloped 
countries  is  high  and  most  of  the  patients  present 
at  advanced  stage.  There  are  also  inadequate  and 
unevenly spread of facilities for early diagnosis and 
effective treatment. Most patients are poor and cannot 
afford adequate treatment. The occurrence of cancer 
in HIV sero positive patient is therefore a challeng-
ing condition in a low resource setting. High morbid-
ity and mortality of HIV positive patients diagnosed 
with cancer are consequently observed at our center. 
Highly Active Anti Retroviral Treatment (HAART) 
improves the outcome of HIV positive patients treated 
for cancer. it improves CD4 count level thus making it 
possible for cancer patients to receive chemotherapy 
and radiotherapy which are important modes of cancer 
treatment. These treatment modalities can also reduce 
the CD4 T- lymphocytes count hence the need to ensure 
their  adequacy  while  on  treatment.4 At  our  center, 
HAART is only commenced in HIV positive patients 
with malignancy if the CD4 T lymphocyte count is 
less than 200 cells/ul. This is based on earlier WHO/
CDC  recommendation  for  ordinary  HIV  positive 
patients. Chemotherapy is usually commenced if the 
CD4 count is at least 200 cells/ul while   Radiotherapy 
can be started in patients who are clinically fit despite 
CD4 count level.
Objective
To evaluate the influence of CD4 T- cell count and 
HAART on cancer treatment compliance and outcome 
of HIV positive patients with cancer managed at the 
oncology service of The University College Hospital, 
Ibadan- South West Nigeria.
patients and Methods
Twenty  two  adult  HIV  positive  patients  with 
malignancies who presented for oncology treatments at 
the hospital from 2007 to 2009 were closely monitored 
by the investigators. Relevant clinical data collected 
included age, sex, HIV status, type of malignancy, CD4 
counts, history of Anti Retroviral Treatment (ART), 
ECOG  performance  status,  prescribed  oncology 
treatment  (chemotherapy/radiotherapy),  consistency 
with  oncology  treatment  and  follow  up  conditions. 
Patients  excluded  from  the  study  were  those  with 
ECOG performance status less than 2, those with no 
histological confirmation of malignancy, those with 
indeterminate  HIV  status  and  those  who  required 
radiotherapy alone. Viral load assay and specification 
of HIV 1 and 11 serotypes were not consistent in the 
patients. Radiotherapy was commenced as indicated 
in all the patients irrespective of CD4 count level. 
Chemotherapy was given if CD4 count was at least 
200 cells/ul. ART naive patients with initial CD4 count 
less than 200 cells/ul were referred to HIV clinic for 
commencement of HAART. CD4 count was repeated 
monthly  during  oncology  treatment  and  thereafter 
three monthly. Chemotherapy was suspended anytime 
the CD4 count value fell below 200 cells/ul.
The procedure for the CD4 count  
assay was as follows
Blood samples were collected from the patients into 
EDTA bottles. Flow cytometry method was used to 
analyze  the  samples  using  CyFlow  SL.3  brand  of 
cytometer which uses green solid state laser with an 
excitation light source of 532 nm. It is connected to 
a computer system with flowmax software used in 
calculating the results. Partec test kit (from Partec 
GmbH  of  Germany)  was  used  in  preparing  the 
samples.  This  test  kit  contains  mouse  monoclonal 
antibody (mAb) isotype IgG1 clone MEM-241 (this 
recognizes the human CD4 antigen) and no lyse buf-
fer. A micropipette is used to withdraw 20 ul of EDTA 
anti coagulated whole blood sample into Rohren test 
tube to which 20 ul of CD4 mAb is added and mixed 
gently. The mixture is incubated in a dark cupboard at 
room temperature for 15 minutes. It is then removed 
and 800 ul of no lyse buffer is added and the mixture 
is shaken gently. The sample is then analyzed on the 
flow cytometer with the help of the computer system CD4 count in hIV patients with cancer
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which displays the results as CD4+ T- cell per ul of 
whole blood.
Results
A total of 22 patients aged between 26 and 67 years 
were evaluated. Nine patients had cancer of the uter-
ine cervix, 4 had non Hodgkin’s lymphoma (NHL), 
3 had nasopharygeal carcinoma, 3 had Kaposis’ sar-
coma while the remaining three had squamous cell 
carcinoma of the right jaw, right eye and breast cancer 
respectively. The performance status of 7 patients was 
ECOG 3 while 15 had ECOG 2. The characteristics 
and treatment outcome of the patients are presented 
in Table 1. From the table, three patients with cancer 
of the cervix had initial CD4 counts of 450, 460 and 
500 cells/ul respectively. They were able to complete 
radiotherapy and chemotherapy as prescribed and were 
not commenced on HAART. Five other patients made 
up of three with cancer of the cervix, one with non 
Hodgkins lymphoma (NHL) and one with cancer of 
the breast were already on HAART before the diagno-
sis of malignancy. Their initial CD4 counts were from 
Table 1. Characteristics and outcome of hIV positive patients treated for malignancies (n = 22).
serial no. Diagnosis Initial cD4 previous HAART Trt compliance Outcome
1 cervix 500 no regular Alive & well
2 cervix 560 no regular Alive & well
3 cervix 450 no regular Alive & well
4 cervix 370 Yes regular Alive & well
5 cervix 360 Yes regular Alive & well
6 cervix 350 Yes regular Alive & well
7 cervix 300 no Irregular Alive + disease
8 cervix + TB 260 Yes Irregular Dead
9 cervix 360 no Irregular Dead
10 breast 360 Yes regular Alive & well
11 nasopharynx 350 no Irregular Alive + disease
12 nasopharynx 270 no Irregular Dead
13 nasopharynx 250 no Irregular Dead
14 nhL 350 Yes regular Alive & well
15 nhL 250 no Irregular Alive + disease
16 nhL 250 no Irregular Alive + disease
17 nhL 150 no Irregular Dead
18 sC rt jaw 280 no Irregular Alive + disease
19 sC rt eye 420 Yes Irregular Alive + disease
20 Ks 180 no Irregular Alive + disease
21 Ks 80 no Irregular Dead
22 Ks 46 no Irregular Dead
Abbreviations: nhL, non hodgkins’ lymphoma; Ks, Kaposis’ sarcoma; sC, squamous cell; Trt, treatment.
350 to 370 cells/ul. They continued with HAART and 
were able to complete their treatments on schedule. 
These five patients were alive and well six months 
after treatment. Eight ART naive patients had initial 
CD4 counts between 250 and 320 cells/ul. All of them 
had values below 200 after one month of treatment. 
They were recommended to start HAART. Chemo-
therapy was suspended except radiotherapy until the 
CD4 count was at least 200. Two out of these patients 
died without completing their treatment while six are 
alive but with recurrent or persistent diseases and are 
on  palliative  care.  One  patient  with  squamous  cell 
carcinoma of the right eye was on HAART. Her initial 
CD4 count was 420 cells/ul. She completed radiother-
apy. Her CD4 count dropped to 120 cells/ul after the 
third course of chemotherapy. Further chemotherapy 
was suspended. Poor nutrition with non adherence to 
HAART were assessed to be contributory to the low 
CD4 count. She is alive with persistent disease. One 
patient with NHL had initial CD4 count of 150 cells/ul. 
This increased to 170 after one month of HAART but 
died before chemotherapy could be commenced. One ntekim and Folasire
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patient with Kaposis’   sarcoma had initial CD4 count 
of 180 cells/ul. He was   commenced on radiotherapy 
and HAART. The CD4 count dropped to 80 cells/ul 
in one month. He is alive but with persistent disease. 
Two other ART naïve patients with Kaposis’ sarcoma 
had  initial  CD4  cells  counts  of  46  and  80  cells/ul 
respectively.  They  were  given  palliative  radiother-
apy and commenced on HAART. They died within 
three  months  of  presentation.  One  cervical  cancer 
patient who was on HAART with initial CD4 count 
of 260 cells/ul was also diagnosed with pulmonary 
tuberculosis and was on anti tuberculosis medications. 
She had palliative radiotherapy but could not receive 
the  recommended  chemotherapy  She  died  within 
4 months of presentation.
Discussion
HIV  infected  patients  are  at  increased  risk  of 
developing  cancer.  Apart  from  AIDS  defining 
cancers like Kaposis’ sarcoma (KS), Non Hodgkins 
lymphoma  (NHL)  and  cervical  cancer,  non  AIDS 
defining cancers are known to occur in excess in HIV 
sero positive patients. Such cancers include Hodgkins’ 
lymphoma, anal cancer, multiple myeloma, leukemia, 
cancers of the lungs, lips, oral cavity, stomach, liver 
pancreas, larynx, vulva, vagina, kidney and childhood 
sarcoma.5–7
CD4  T-  cell  count  serves  as  the  major  clinical 
indicator  of  immunocompetence  in  patients  with 
HIV infection and hence usually the most important 
consideration in decision to initiate ART.8 The use of 
HAART enables these patients to be treated as their 
immunocompetent  counterparts  with  improved  out-
come.9  The  benefits  of  HAART  include  decreased 
development of HIV associated malignancies, higher 
CD4  count  levels,  improved  tolerance  of  full  dose 
of  chemotherapy,  improved  response  rates,  dura-
tion  of  response  and  survival  during  treatment  of 
malignancy.10
The  WHO  and  USA  Department  of  Health 
and  Human  Services  (DHHS)  have  updated  their 
recommendations  on  the  commencement  of ART 
in HIV positive patients to include those with CD4 
count of 350 cells/ul or less in addition to the man-
datory treatment of those with CD4 count less than 
200 cells/ul which is still being used as the level for 
the   commencement of ART in many places includ-
ing our center. According to these guidelines, data 
from an ART cohort collaboration which included 
61798 patients-years of follow up showed that at 
3–5 years after starting ART, the risk of AIDS/death 
was significantly less in those who started therapy 
with CD4 T- cell count between 200 and 350 com-
pared with those who initiated ART at a CD4 thresh-
old of 200 cells/ul. Also the risk of opportunistic 
diseases and non AIDS events like hepatic failure, 
renal  and  cardiovascular  diseases  with  non AIDS 
malignancies  were  higher  in  patients  whose ART 
was deferred till CD4 count dropped to ,250 cells/ul 
than in those who commenced treatment with CD4 
count .350 cells/ul. There is also a recommenda-
tion that patients scenarios and co morbidities should 
be taken into consideration in starting ART in CD4 
count .350 cells/ul.11,12 The recent WHO recom-
mendation to commence antiretroviral therapy when 
CD4 count is less than or equal to 350 cells/ul is 
for all HIV positive patients either symptomatic or 
not. In that same document under key recommen-
dations on when to start treatment, ART should be 
commenced on all HIV positive patients with WHO 
stages 3 and 4 diseases irrespective of CD4 count. 
The WHO stage 4 disease includes lymphoma and 
cervical cancer which are malignant diseases.13 This 
implies  that  patients  with  confirmed  diagnosis  of 
above conditions should be commenced on ART as 
soon as the diagnosis is made whether CD4 count 
is above 350 cells/ul or less. The panel placed high 
value  on  avoiding  death,  disease  progression  and 
HIV transmission over and above cost and feasibil-
ity in making these recommendations according to 
the report. This study though has small number of 
patients, is able to show that this group of patients 
needs separate approach to treatment as in other HIV 
associated situations like tuberculosis and infancy 
instead of approaching their treatment as ordinary 
HIV positive patients. This brings out the need for 
well planned studies in low resource settings to guide 
in developing management guideline that will help 
in improving the outcome of their treatment. Such 
studies might need to consider such factors like viral 
load, treatment failure and viral replication in sup-
pressing improvements in CD4 cells count in HIV 
positive patients diagnosed with cancer.
In the developed countries, starting ART at CD4 count 
of 350 cells/ul or higher has been shown to be associated 
with significant reduction in the risk of death.14,15CD4 count in hIV patients with cancer
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This study shows that in our environment,   waiting 
to commence HAART in HIV positive patients on 
oncology treatment when CD4 count is ,200 cells/ul 
resulted in poor outcome. Patients with CD4 counts 
between 200 and 350 were not regular in their treat-
ments due to drop in their CD4 counts below 200 
resulting in poor outcome.
Chemotherapy  has  been  successfully  given  to 
patients with CD4 cell counts less than 200 cells/ul 
mostly in developed countries. Such patients usually 
have the benefit of having haemopoetic agents like 
Granulocyte Colony Stimulating Factor (G-CSF) and 
erythropoietin. Autologous stem cell transplantation is 
recommended in cases of refractory or relapsed HIV 
associated lymphoma.16 These agents are expensive 
in our center and hardly affordable by these patients 
most of whom are poor. Facilities for some of these 
interventions  including  those  for  early  diagnosis 
and  treatment  of  opportunistic  infections  are  poor. 
Prophylaxis  against  pneumocystis  pneumonia  and 
mycobacterium avium are recommended in patients 
with CD4 cell counts less than 200 and 50 cells/iu 
respectively by the USA Department of Health and 
Human Services. The five patients with CD4 counts of 
370 cells/ul who were already on HAART were able 
to complete their treatments on schedule confirming 
the benefit of HAART while on treatment. There is a 
report of a series of HIV positive patients with anal car-
cinoma where HAART was given to all patients even 
with CD4 count of 500 and above. They all received 
standard  oncology  treatments  and  had  comparable 
results with HIV negative patients.17 This shows that 
HAART can be commenced on those patients with 
higher  CD4  count  levels  to  ensure  completion  of 
oncology treatment in order to have comparable out-
come with their HIV seronegative counterparts. There 
are concerns that  ART are started too late in HIV positive 
patients in undeveloped countries when many patients 
are already immunocompromised hence an increase 
in the point of intervention to 400 or 450 cells/ul has 
been advocated.18 The incidence of mortality has been 
shown to be higher in those who started ART with 
CD4 count less than 350 cells/ul.19 The situation is thus 
very critical in HIV positive patients diagnosed with 
cancer because the malignancy itself and the modes 
of treatment which include surgery, chemotherapy and 
radiotherapy can all potentiate immunosuppression.20 
Most patients in low income countries do not have 
optimal  nutritional  status  thereby  worsening  their 
immune states when challenged with above factors in 
addition to HIV infection. The earlier commencement 
of HAART in cancer patients with HIV infection may 
increase the number of patients requiring HAART but 
this increase is in a small cohort of patients. This will 
enable them to be treated as their sero positive coun-
terparts with close monitoring of their CD4 counts. 
Compliance with anti retroviral medications should 
also be monitored in these patients as this is an impor-
tant determinant of benefit with HAART.21
conclusion
Based on these observations, our assessment is that 
malignancy is an important co morbidity in HIV 
positive patients in low resource countries neces-
sitating the early commencement of HAART. We 
therefore recommend that HAART should be com-
menced  on  all  HIV  positive  patients  diagnosed 
with malignancy with an initial CD4 count below 
450  cells/ul  in  our  environment  to  enable  them 
complete their oncology treatments on schedule and 
CD4 count should be monitored in all such patients 
monthly  until  completion  of  oncology  treatment. 
Further studies in low resource settings with appro-
priate sample size are however needed to validate 
these findings.
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